Pharmacokinetic study
Conditions
Interventions
Experimental group:Test preparation fluticasone propionate aerosol inhalation suspension (specification: 2ml: 0.5mg, license holder: Hunan Xianshi Pharmaceutical Co., Ltd.)
Control Group:Fluticasone Propionate Nebulized Inhalation Suspension (trade name: Flixotide Nebules? / Flixotide?, Specification: 2ml: 0.5mg, Manufacturer: GlaxoSmithKline Australia Pty Ltd.)
Sponsors
Dongyang Hengdian Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Healthy adult males and non-pregnant non-breastfeeding females, aged 18 to 55 years (including 18 and 55 years old, those over 55 years old during the test period are not excluded); 2. Male weight >= 50kg, female weight >= 45kg, body mass index (BMI) between 19~28kg/m2, including the boundary value; 3. Physical health, no medical history of heart, liver, kidney, digestive tract, nervous system, mental disorders and metabolic diseases judged by the researchers to have an impact on this research; 4. Sign the informed consent form before the trial, fully understand the trial content, process and possible adverse reactions, and communicate well with the investigator.
Exclusion criteria
Exclusion criteria: 1. Participated in any clinical trial within 90 days before the trial, or planned to participate in other clinical trials during the trial; 2. Have undergone major surgery within 90 days before the trial or plan to undergo surgery within 3 months after the trial; 3. Lost blood or donated more than 300 mL of blood within 90 days before the test (excluding the blood loss of women during menstrual period), or received blood transfusion; 4. Patients with esophageal reflux, gastric bleeding or peptic ulcer disease (such as colitis) within 180 days before the test, heartburn more than once a week, or any surgical operation (such as cholecystectomy) that may affect drug absorption; 5. Those with a history of specific allergies (asthma, urticaria, eczema, etc.), or allergic constitution (such as allergies to two or more drugs, food or pollen), or known allergies to the components of this medicine or analogs; 6. The use of any drugs within 14 days before the trial [including the use of prescription drugs, over-the-counter drugs and/or alternative drugs (such as medicated diets, Chinese herbal medicines, hemostatic and blood-activating plants or health products), and the use of hormonal contraception or vaccines] or the investigator considers it inappropriate to participate in the trial; 7. Have a history of psychotropic substance abuse; 8. Positive urine screening for drug abuse (tetrahydrocannabinol acid, benzodiazepines, barbiturates, morphine, cocaine, methamphetamine); 9. Smoking more than 5 cigarettes per day on average in the 90 days before the test; addicted to alcohol, drinking more than 7 drinks per week for women or more than 14 drinks per week for men within 28 days before the trial (1 glass = 150 mL of wine = 360 mL of beer = 45 mL of spirits) ; 10. Positive alcohol breath test; 11. Body temperature (ear temperature) >= 37.5 degree, obvious abnormal breathing and the investigator thinks it is not suitable to participate in the test, sitting systolic blood pressure > 140mmHg or 90 mmHg or 100 times/min; 12. Human immunodeficiency virus (HIV-Ab), hepatitis B surface antigen (HBsAg), hepatitis C (anti-HCV) or syphilis antibody (TP) positive; 13. There are special requirements for diet, and the unified diet cannot be followed during the test; 14. Subjects refuse to comply with the prohibition of beverages and foods (including tea, chocolate, coffee, cola, etc.) containing caffeine, alcohol, and grapefruit 48 hours before taking the medicine; 15. Subjects with partners refuse to use effective contraception within 180 days from screening to completion of the trial; 16. Positive pregnancy test for female subjects; 17. The subject has oral ulcers; 18. There are obvious abnormalities in the physical examination and the investigator considers it unsuitable to participate in the trial; 19. There are obvious abnormalities in the electrocardiogram examination and the investigator believes that it is not suitable to participate in the trial; 20. There are obvious abnormalities in blood biochemistry, blood routine, and urine routine examinations and the investigators believe that they are not suitable to participate in the trial; 21. People who are dizzy with needles, dizzy blood, or difficult to collect blood from veins; 22. Subjects may not be able to complete this trial for other reasons or judged by the investigator to be unsuitable to
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| peak concentration;Area under the drug-time curve from zero to t;Area under the drug-time curve from zero to infinity; | — |
Countries
China
Contacts
Public ContactJIn Feiyan
Dongyang Hengdian Hospital
Outcome results
None listed